Although not involving multiplex gene editing, generation of PD-1 deficient T-cells via CRISPR-Cas9 editing of PDCD1 was also demonstrated to be feasible in the setting of clinical product scalability, and this product proved to be safe in a phase I trial for advanced non-small-cell lung cancer patients [4]. Here, PDCD1 is linked to non-small cell lung carcinoma.